Lifecome Biochemistry Co Ltd
Lifecome Biochemistry Co.,Ltd. operates as a biopharmaceutical company in China. It offers bacitracin zinc products, colistin sulfate products, probiotics products, bacitracin methylene disalicylate products, biological preservatives, photovoltaic film products, etc.; veterinary drugs; and food preservatives. The company was founded in 2003 and is based in Pucheng, China.
Market Cap & Net Worth: Lifecome Biochemistry Co Ltd (002868)
Lifecome Biochemistry Co Ltd (SHE:002868) has a market capitalization of $863.79 Million (CN¥6.34 Billion) as of March 18, 2026. Listed on the SHE stock exchange, this China-based company holds position #10363 globally and #2293 in its home market, demonstrating a -3.18% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lifecome Biochemistry Co Ltd's stock price CN¥40.78 by its total outstanding shares 155415837 (155.42 Million).
Lifecome Biochemistry Co Ltd Market Cap History: 2017 to 2026
Lifecome Biochemistry Co Ltd's market capitalization history from 2017 to 2026. Data shows growth from $377.25 Million to $853.20 Million (11.22% CAGR).
Lifecome Biochemistry Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lifecome Biochemistry Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.65x
Lifecome Biochemistry Co Ltd's market cap is 0.65 times its annual revenue
1742.66x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $377.25 Million | $375.41 Million | $85.92 Million | 1.00x | 4.39x |
| 2018 | $233.91 Million | $344.29 Million | $74.69 Million | 0.68x | 3.13x |
| 2019 | $285.87 Million | $303.76 Million | $56.97 Million | 0.94x | 5.02x |
| 2020 | $278.97 Million | $308.15 Million | $43.21 Million | 0.91x | 6.46x |
| 2021 | $233.64 Million | $363.39 Million | -$26.44 Million | 0.64x | N/A |
| 2022 | $1.12 Billion | $329.85 Million | -$122.72 Million | 3.41x | N/A |
| 2023 | $450.32 Million | $507.00 Million | -$221.82 Million | 0.89x | N/A |
| 2024 | $423.00 Million | $649.37 Million | -$444.86 Million | 0.65x | N/A |
Competitor Companies of 002868 by Market Capitalization
Companies near Lifecome Biochemistry Co Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Lifecome Biochemistry Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #158 globally with a market cap of $118.01 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.58 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #158 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $118.01 Billion | $466.10 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.58 Billion | $756.91 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Lifecome Biochemistry Co Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, Lifecome Biochemistry Co Ltd's market cap moved from $377.25 Million to $ 853.20 Million, with a yearly change of 11.22%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥853.20 Million | +19.49% |
| 2025 | CN¥714.04 Million | +68.80% |
| 2024 | CN¥423.00 Million | -6.07% |
| 2023 | CN¥450.32 Million | -59.95% |
| 2022 | CN¥1.12 Billion | +381.32% |
| 2021 | CN¥233.64 Million | -16.25% |
| 2020 | CN¥278.97 Million | -2.41% |
| 2019 | CN¥285.87 Million | +22.21% |
| 2018 | CN¥233.91 Million | -38.00% |
| 2017 | CN¥377.25 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Lifecome Biochemistry Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $863.79 Million USD |
| MoneyControl | $863.79 Million USD |
| MarketWatch | $863.79 Million USD |
| marketcap.company | $863.79 Million USD |
| Reuters | $863.79 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.